{"id":73032,"date":"2021-05-11T13:33:00","date_gmt":"2021-05-11T11:33:00","guid":{"rendered":"https:\/\/cms.munich-startup.net\/?p=73032"},"modified":"2021-05-11T10:51:55","modified_gmt":"2021-05-11T08:51:55","slug":"corona-caused-record-investments-in-biotech-in-2020","status":"publish","type":"post","link":"https:\/\/cms.munich-startup.net\/en\/73032\/corona-caused-record-investments-in-biotech-in-2020\/","title":{"rendered":"Corona led to record investments in biotech in 2020"},"content":{"rendered":"<div class=\"entry-content\">\n<p>As the analysis \u201cBiotech at the Tipping Point\u201d <a href=\"https:\/\/assets.ey.com\/content\/dam\/ey-sites\/ey-com\/de_de\/news\/2021\/04\/ey-deutscher-biotechnologie-report-april-2021.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">the auditors of EY<\/a> According to the report, German biotech companies raised approximately \u20ac2.56 billion through equity financing in the form of venture capital, IPOs, and follow-on financing. In addition, capital was raised in the form of convertible bonds totaling over \u20ac482 million. All in all, this represents an increase of 146 percent compared to the previous record year of 2018.<\/p>\n\n\n\n<p>This development was particularly influenced by individual events, which in turn were strongly influenced by the coronavirus pandemic. BioNTech and CureVac, both of which have developed vaccines against COVID-19, alone accounted for more than half of the total capital raised, at \u20ac1.55 billion.<\/p>\n\n\n\n<p>The venture capital entrusted to biotech startups totaled \u20ac882 million in 2020. This represents an increase of 84 percent over the previous year. This continues the positive trend in total VC inflows for the third consecutive year. There was already a very strong increase of 92 percent from 2017 to 2018, and a 24 percent increase from 2018 to 2019.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Germany ahead of France and behind Great Britain<\/h2>\n\n\n\n<p>In a European comparison, Germany left France far behind last year. In 2019, both countries were on par with venture capital of \u20ac479 million each, but the French biotech landscape was unable to replicate German growth. Instead, startups across the Rhine raised \u20ac386 million, even less than the previous year. Switzerland, however, moved into third place behind Germany with \u20ac402 million in venture capital. However, the Swiss&#039; total VC value stagnated at the previous year&#039;s level. The European leader remains the United Kingdom, where the volume doubled to almost \u20ac1.1 billion.<\/p>\n\n\n\n<p>However, this analysis once again reveals the impact of certain individual events. Without the venture capital rounds for CureVac, Germany would be at the bottom of the list compared to these four countries. The company raised a total of \u20ac560 million in venture capital in 2020.<\/p>\n\n\n\n<p>Overall, European biotech companies raised \u20ac16.2 billion last year, representing growth of approximately 25 percent. In the US, however, the biotech industry raised $99.36 billion, nearly doubling its capital raising compared to the previous year (+90 percent).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Fewer start-ups, Munich remains a stronghold<\/h2>\n\n\n\n<p>The situation regarding new start-ups, however, is less positive. While 29 biotech companies were founded in Germany last year, the number fell to just 19 in 2020. The study cites the pandemic lockdown and the loss of <a href=\"\/en\/dates\/\">In-person events for the startup scene<\/a> to.<\/p>\n\n\n\n<p>From a regional perspective, there continues to be a clear north-south divide in new startups. Bavaria (6 startups, or 32 percent) and Baden-W\u00fcrttemberg (4; 21 percent) account for over half of the new startups, closely followed by North Rhine-Westphalia (3; 16 percent), Berlin, and Lower Saxony (2 each; 11 percent). Saxony-Anhalt and Rhineland-Palatinate each recorded one startup. In the two leading states, startups remain strongly focused on the established strongholds of Munich (4), including its catchment areas (Wolfratshausen and Polling), and Heidelberg (2, Heidelberg and Ketsch), as well as T\u00fcbingen and Freiburg im Breisgau (Stegen).<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>German biotechnology companies are chasing records with their financing: last year they raised a total of almost 3.1 billion euros in fresh capital, more money than ever before.<\/p>","protected":false},"author":33,"featured_media":73033,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[5633,5634,1],"tags":[371,2175,52,157],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.1.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Corona sorgte 2020 f\u00fcr Rekord-Investments in Biotech - Munich Startup<\/title>\n<meta name=\"description\" content=\"Deutsche Biotech-Unternehmen haben im vergangenen Jahr knapp 3,1 Milliarden Euro frisches Kapital eingesammelt, so viel wie noch nie.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cms.munich-startup.net\/en\/73032\/corona-caused-record-investments-in-biotech-in-2020\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Corona sorgte 2020 f\u00fcr Rekord-Investments in Biotech - Munich Startup\" \/>\n<meta property=\"og:description\" content=\"Deutsche Biotech-Unternehmen haben im vergangenen Jahr knapp 3,1 Milliarden Euro frisches Kapital eingesammelt, so viel wie noch nie.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cms.munich-startup.net\/en\/73032\/corona-caused-record-investments-in-biotech-in-2020\/\" \/>\n<meta property=\"og:site_name\" content=\"Munich Startup\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/munichstartup\/\" \/>\n<meta property=\"article:published_time\" content=\"2021-05-11T11:33:00+00:00\" \/>\n<meta name=\"author\" content=\"Maximilian Feigl\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@munich_startup\" \/>\n<meta name=\"twitter:site\" content=\"@munich_startup\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Maximilian Feigl\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cms.munich-startup.net\/73032\/corona-sorgte-2020-fuer-rekord-investments-in-biotech\/\",\"url\":\"https:\/\/cms.munich-startup.net\/73032\/corona-sorgte-2020-fuer-rekord-investments-in-biotech\/\",\"name\":\"Corona sorgte 2020 f\u00fcr Rekord-Investments in Biotech - Munich Startup\",\"isPartOf\":{\"@id\":\"https:\/\/cms.munich-startup.net\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cms.munich-startup.net\/73032\/corona-sorgte-2020-fuer-rekord-investments-in-biotech\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cms.munich-startup.net\/73032\/corona-sorgte-2020-fuer-rekord-investments-in-biotech\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2021\/05\/analysis-2030261_1920.jpg\",\"datePublished\":\"2021-05-11T11:33:00+00:00\",\"author\":{\"@id\":\"https:\/\/cms.munich-startup.net\/#\/schema\/person\/40ec2127e0b2a722f0cb734a53f43509\"},\"description\":\"Deutsche Biotech-Unternehmen haben im vergangenen Jahr knapp 3,1 Milliarden Euro frisches Kapital eingesammelt, so viel wie noch nie.\",\"breadcrumb\":{\"@id\":\"https:\/\/cms.munich-startup.net\/73032\/corona-sorgte-2020-fuer-rekord-investments-in-biotech\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cms.munich-startup.net\/73032\/corona-sorgte-2020-fuer-rekord-investments-in-biotech\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cms.munich-startup.net\/73032\/corona-sorgte-2020-fuer-rekord-investments-in-biotech\/#primaryimage\",\"url\":\"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2021\/05\/analysis-2030261_1920.jpg\",\"contentUrl\":\"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2021\/05\/analysis-2030261_1920.jpg\",\"width\":1920,\"height\":1279,\"caption\":\"Biotech\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cms.munich-startup.net\/73032\/corona-sorgte-2020-fuer-rekord-investments-in-biotech\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cms.munich-startup.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Corona sorgte 2020 f\u00fcr Rekord-Investments in Biotech\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cms.munich-startup.net\/#website\",\"url\":\"https:\/\/cms.munich-startup.net\/\",\"name\":\"Munich Startup\",\"description\":\"Das offizielle Startup-Portal f\u00fcr M\u00fcnchen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cms.munich-startup.net\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/cms.munich-startup.net\/#\/schema\/person\/40ec2127e0b2a722f0cb734a53f43509\",\"name\":\"Maximilian Feigl\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cms.munich-startup.net\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/194fab98a3d18da0d43ab2b73b348908?s=96&d=blank&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/194fab98a3d18da0d43ab2b73b348908?s=96&d=blank&r=g\",\"caption\":\"Maximilian Feigl\"},\"description\":\"Maximilian Feigl berichtet seit 2020 \u00fcber das M\u00fcnchner Startup \u00d6kosystem. Dabei haben es dem studierten Politikwissenschaftler vor allem Deeptech-Themen angetan.\",\"url\":\"https:\/\/cms.munich-startup.net\/en\/author\/feigl\/\"}]}<\/script>\n<meta property=\"og:image\" content=\"https:\/\/cms.munich-startup.net\/en\/wp-content\/uploads\/2021\/05\/analysis-2030261_1920.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1279\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Corona led to record investments in biotech in 2020 - Munich Startup","description":"German biotech companies raised almost 3.1 billion euros in fresh capital last year, more than ever before.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cms.munich-startup.net\/en\/73032\/corona-caused-record-investments-in-biotech-in-2020\/","og_locale":"en_US","og_type":"article","og_title":"Corona sorgte 2020 f\u00fcr Rekord-Investments in Biotech - Munich Startup","og_description":"Deutsche Biotech-Unternehmen haben im vergangenen Jahr knapp 3,1 Milliarden Euro frisches Kapital eingesammelt, so viel wie noch nie.","og_url":"https:\/\/cms.munich-startup.net\/en\/73032\/corona-caused-record-investments-in-biotech-in-2020\/","og_site_name":"Munich Startup","article_publisher":"https:\/\/www.facebook.com\/munichstartup\/","article_published_time":"2021-05-11T11:33:00+00:00","author":"Maximilian Feigl","twitter_card":"summary_large_image","twitter_creator":"@munich_startup","twitter_site":"@munich_startup","twitter_misc":{"Written by":"Maximilian Feigl","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/cms.munich-startup.net\/73032\/corona-sorgte-2020-fuer-rekord-investments-in-biotech\/","url":"https:\/\/cms.munich-startup.net\/73032\/corona-sorgte-2020-fuer-rekord-investments-in-biotech\/","name":"Corona led to record investments in biotech in 2020 - Munich Startup","isPartOf":{"@id":"https:\/\/cms.munich-startup.net\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cms.munich-startup.net\/73032\/corona-sorgte-2020-fuer-rekord-investments-in-biotech\/#primaryimage"},"image":{"@id":"https:\/\/cms.munich-startup.net\/73032\/corona-sorgte-2020-fuer-rekord-investments-in-biotech\/#primaryimage"},"thumbnailUrl":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2021\/05\/analysis-2030261_1920.jpg","datePublished":"2021-05-11T11:33:00+00:00","author":{"@id":"https:\/\/cms.munich-startup.net\/#\/schema\/person\/40ec2127e0b2a722f0cb734a53f43509"},"description":"German biotech companies raised almost 3.1 billion euros in fresh capital last year, more than ever before.","breadcrumb":{"@id":"https:\/\/cms.munich-startup.net\/73032\/corona-sorgte-2020-fuer-rekord-investments-in-biotech\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cms.munich-startup.net\/73032\/corona-sorgte-2020-fuer-rekord-investments-in-biotech\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cms.munich-startup.net\/73032\/corona-sorgte-2020-fuer-rekord-investments-in-biotech\/#primaryimage","url":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2021\/05\/analysis-2030261_1920.jpg","contentUrl":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2021\/05\/analysis-2030261_1920.jpg","width":1920,"height":1279,"caption":"Biotech"},{"@type":"BreadcrumbList","@id":"https:\/\/cms.munich-startup.net\/73032\/corona-sorgte-2020-fuer-rekord-investments-in-biotech\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cms.munich-startup.net\/"},{"@type":"ListItem","position":2,"name":"Corona sorgte 2020 f\u00fcr Rekord-Investments in Biotech"}]},{"@type":"WebSite","@id":"https:\/\/cms.munich-startup.net\/#website","url":"https:\/\/cms.munich-startup.net\/","name":"Munich Startup","description":"The official startup portal for Munich","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cms.munich-startup.net\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/cms.munich-startup.net\/#\/schema\/person\/40ec2127e0b2a722f0cb734a53f43509","name":"Maximilian Feigl","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cms.munich-startup.net\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/194fab98a3d18da0d43ab2b73b348908?s=96&d=blank&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/194fab98a3d18da0d43ab2b73b348908?s=96&d=blank&r=g","caption":"Maximilian Feigl"},"description":"Maximilian Feigl has been reporting on the Munich startup ecosystem since 2020. The political scientist is particularly interested in deeptech topics.","url":"https:\/\/cms.munich-startup.net\/en\/author\/feigl\/"}]},"og_image":[{"width":1920,"height":1279,"url":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2021\/05\/analysis-2030261_1920.jpg","type":"image\/jpeg"}]},"_showyear":"","_inactive":"","_show_financing":"","_hide_on_map":"","_edit_lock":"1620738368:33","_edit_last":"33","_yoast_wpseo_focuskw":"Biotech","_yoast_wpseo_metadesc":"Deutsche Biotech-Unternehmen haben im vergangenen Jahr knapp 3,1 Milliarden Euro frisches Kapital eingesammelt, so viel wie noch nie.","_yoast_wpseo_linkdex":"73","_thumbnail_id":"73033","wbounce_status":"default","_yoast_wpseo_primary_category":"5633","_yoast_wpseo_focuskw_text_input":"","_yoast_wpseo_content_score":"90","ms_image_format":"contentwidth","_ms_image_format":"field_5cb8587572c8b","ms_dachzeile":"","_ms_dachzeile":"field_5cd9b7f365df5","ms_bump_post_date":"","_ms_bump_post_date":"field_5d1341edcf42a","guest_author_name":"","_guest_author_name":"field_5cee78a6016f9","guest_author_image":"","_guest_author_image":"field_5cee7914016fb","guest_author_description":"","_guest_author_description":"field_5cee78dd016fa","ms_post_image_caption":"","_ms_post_image_caption":"field_5f735b0735284","ms_post_image_credit":"","_ms_post_image_credit":"field_5f735b1435285","suppress_startupbox":"","_suppress_startupbox":"","_yoast_wpseo_estimated-reading-time-minutes":"3","_wp_old_date":"","_yoast_wpseo_title":"","_yoast_wpseo_wordproof_timestamp":"","footnotes":"","easy_language_simplification_original_id":"","easy_language_source_language":"","easy_language_simplification_language":"","easy_language_api":"","easy_language_prevent_automatic_mode":"","_wp_old_slug":"","_wp_trash_meta_status":"","_wp_trash_meta_time":"","easy_language_simplification_state_changed_from":"","easy_language_de_EL_changed":"","ms_competition_deadline":"","_ms_competition_deadline":"","_wpbitly":"","enclosure":"","_yoast_wpseo_meta-robots-noindex":"","_yoast_wpseo_meta-robots-nofollow":"","wbounce_template":"","wbounce_title":"","wbounce_text":"","wbounce_cta":"","wbounce_url":"","wbounce_override":"","_yoast_wpseo_opengraph-title":"","_yoast_wpseo_opengraph-description":"","_oembed_7131efca3705e16bd9da2c41df237660":"","_oembed_time_7131efca3705e16bd9da2c41df237660":"","_pprredirect_type":"","_pprredirect_url":"","_yoast_wpseo_opengraph-image":"","_yoast_wpseo_opengraph-image-id":"","_newsletterglue":"","easy_language_text_language":"","_wp_desired_post_slug":"","_relevanssi_noindex_reason":"","_links":{"self":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts\/73032"}],"collection":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/users\/33"}],"replies":[{"embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/comments?post=73032"}],"version-history":[{"count":1,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts\/73032\/revisions"}],"predecessor-version":[{"id":73034,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts\/73032\/revisions\/73034"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/media\/73033"}],"wp:attachment":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/media?parent=73032"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/categories?post=73032"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/tags?post=73032"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}